Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes: A pilot study by Cherney, David Z.I. et al.
Effect of Direct Renin Inhibition on Renal
Hemodynamic Function, Arterial Stiffness,
and Endothelial Function in Humans With
Uncomplicated Type 1 Diabetes
A pilot study




JAMES W. SCHOLEY, MD
1




HEATHER N. REICH, MD, PHD
1
OBJECTIVE — Blockade of the renin-angiotensin system (RAS) plays an important role in
preventing end-organ injury associated with diabetes. The recent development of direct renin
inhibitors (DRIs) provides a new approach to block the RAS, but the effects of DRIs on renal and
systemic vascular function in uncomplicated type 1 diabetes have not been elucidated.
RESEARCH DESIGN AND METHODS — Renal hemodynamic function (inulin and
paraaminohippurate clearance), augmentation index and pulse wave velocity, endothelial de-
pendent vasodilatation (ﬂow-mediated dilation [FMD]), and endothelial independent vasodila-
tation (response to sublingual nitroglycerin) were evaluated before and after administration of
aliskiren (300 mg daily for 30 days) in 10 adult subjects with uncomplicated type 1 diabetes
during clamped euglycemia (4–6 mmol/l) and hyperglycemia (9–11 mmol/l).
RESULTS — In response to the DRI, plasma renin activity decreased (from 0.40 to 0.13 ng  
ml
1   h
1, P  0.05) and plasma renin increased (from 5.2 to 75.0 ng/l, P  0.05). Peripheral
and central blood pressures decreased, and effective renal plasma ﬂow and glomerular ﬁltration
rate increased during clamped euglycemia and hyperglycemia (P  0.05). The carotid augmen-
tation index during clamped euglycemia decreased (from 26  6t o2 0 5%, P  0.05) as did
pulsewavevelocityduringclampedhyperglycemia(from7.80.6to6.80.5m/s,P0.05).
In response to the DRI, FMD increased during both clamped euglycemia (from 1.92  1.13 to
5.55  0.81%) and hyperglycemia (from 1.86  0.98 to 5.63  0.62) as did the vasodilatory
response to sublingual nitroglycerin.
CONCLUSIONS — DRIs exert a renal vasodilatory effect and improve parameters of sys-
temic vascular function, suggesting that blockade of the RAS with this new class of agents has
important functional effects in subjects with uncomplicated type 1 diabetes.
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D
iabetes renal complications are, in
part, mediated by activation of the
renin-angiotensin system (RAS),
which leads to maladaptive renal and sys-
temic hemodynamic responses including
renal hyperﬁltration, increased arterial
stiffness, and endothelial dysfunction (1–
3). More recently, a new class of RAS in-
hibitors, called direct renin inhibitors
(DRIs), has become available. DRIs block
the generation of angiotensin I from an-
giotensinogen, thereby preventing the
generation of angiotensin II (one of the
main effectors of the RAS). DRIs also mit-
igate the cellular effects of prorenin and
renin on the prorenin receptor, thereby
accounting for the prominent hemody-
namic effects of DRIs in animals and hu-
mans (4). From a functional perspective,
the addition of a DRI to an angiotensin
receptor blocker (ARB) or ACE inhibitor
(ACEI) provides additional antihyperten-
sive effects (4). In humans with type 2
diabetes and clinical evidence of diabetic
nephropathy, DRIs such as aliskiren
(Rasilez; Novartis Pharmaceuticals Can-
ada) exert antiproteinuric effects that are
additive to those of ARBs, suggesting that
DRIs may speciﬁcally enhance blockade
of the intrarenal RAS in humans (5). Use
of a DRI is therefore an attractive strategy
to block the RAS in conditions in which
theRASisactivated,suchasdiabetes,and
may provide incremental protective he-
modynamic effects in humans when
added to ACEI or ARB therapy (4).
However, the renal and peripheral
vascular hemodynamic effects of DRI
monotherapy have not been studied in
human subjects with uncomplicated type
1 diabetes. Accordingly, the objective of
this pilot study was to examine the renal
hemodynamicandperipheralvascularef-
fects of a DRI using aliskiren in subjects
with uncomplicated type 1 diabetes,
when RAS activation may promote the
cellular and hemodynamic changes that
contribute to the development of diabetic
nephropathy and vascular complications
(6).
RESEARCH DESIGN AND
METHODS— Five men and ﬁve
womenwithuncomplicatedtype1diabe-
tes participated in this pilot study (Table
1). Inclusion criteria were duration of
type1diabetes10years,age16years,
blood pressure 140/90, and no history
of renal disease or macrovascular disease.
No subjects had microalbuminuria (per-
sistent urinary albumin-to-creatinine ra-
tio 2.1 mg/mmol in men or 2.8 mg/
mmol in women). Female subjects were
studied during the late follicular phase of
the menstrual cycle, determined by cycle
day and measurement of 17-estradiol
levels. None were using oral contracep-
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boards at the University Health Network
and Hospital for Sick Children (Toronto,
ON, Canada) approved the protocol, and
all subjects gave informed consent.
Subjects adhered to a high-sodium
(150 mmol/day) and moderate-protein
(1.5g/kg/day)dietduringthe7-daype-
riodbeforeeachexperiment,asdescribed
previously (Table 1). Euglycemic (4–6
mmol/l) and hyperglycemic (9–11
mmol/l) conditions were maintained on
two consecutive days for 6 h preceding
and during all investigations, a period of
time demonstrated to be sufﬁcient for de-
tection of changes in vascular function
(7).Inallphasesoftheexperiment,blood
glucose was maintained by a modiﬁed
glucose clamp technique, as described
previously (8). A 16-gauge peripheral ve-
nous cannula was inserted into the left
antecubital vein for infusion of glucose
and insulin and a second cannula was in-
serted for blood sampling more distally.
Bloodglucosewasmeasuredevery10–15
min, and the insulin infusion was ad-
justed to maintain the desired glycemic
level. All experiments were performed in
the same warm (25°C), temperature-
controlled room and in a dark, quiet en-
vironment after 10 min of rest in the
supine position. Renal and systemic vas-
cular function studies were performed at
baseline and then repeated in an identical
fashion after 30 days of aliskiren therapy
(300 mg orally/day).
Assessment of arterial stiffness and
endothelial function
After the glucose clamp, peripheral blood
pressure was measured in the right bra-
chialarterywithanautomatedDINAMAP
sphygmomanometer (Critikon, Tampa,
FL). Right carotid artery waveforms were
recorded with a high-ﬁdelity microma-
nometer (SPC-301; Millar Instruments),
and with use of the validated transfer
function, corresponding central aortic
pressure waveform and central blood
pressure data were generated (Sphygmo-
Cor; AtCor Medical Systems, Sydney,
Australia). Mean arterial pressure and
heart rate were determined using the in-
tegral software. Augmentation index, an
estimate of systemic arterial stiffness, was
calculated as the difference between the
second systolic peak and inﬂection point,
expressed as a percentage of the central
pulse pressure corrected to an average
heart rate of 75 bpm. The aortic pulse
wave velocity was measured using the
same device by sequentially recording
electrocardiogram-gatedrightcarotidand
femoral artery waveforms. The interop-
erator variability and reproducibility of
the augmentation index have been vali-
dated to be 0.4  6.4%. Our group has
published and validated the use of the
SphygmoCor device (9).
Brachial artery endothelial function
was determined by recording diameter
changes in the brachial artery in response
to increased blood ﬂow generated during
reactive hyperemia (ﬂow-mediated dila-
tation [FMD]) and glyceryl trinitrate-
induced dilatation (GTN). In brief, the
right brachial artery was scanned 2–5 cm
above the antecubital fossa using high-
resolution B-mode vascular ultrasound
(Vividi, 7–15 MHz linear-array trans-
ducer; GE/Vingmed, Waukesha, WI).
Longitudinal, electrocardiogram-gated,
end-diastolic images were acquired over
six cardiac cycles, the brachial arterial di-
ameterwasdeterminedforeachimageus-
ing integrated software, and the results
were averaged. Diameter measurements
were taken from the anterior to the pos-
terior interface between the media and
adventitia (7). After baseline images were
recorded, the blood pressure cuff was in-
ﬂated around the forearm distal to the el-
bow to 200 mmHg for 5 min. After cuff
deﬂation, the increase in blood ﬂow was
measured (reactive hyperemia) along
with the change in vessel diameter (endo-
thelium-dependent dilatation), which
was measured for a further 5 min. GTN
(400 g) was then administered sublin-
gually, and the changes were measured
over a further 5 min (endothelium-
independent dilatation). FMD and GTN
were deﬁned as the maximal percent
changes in vessel diameter after reactive
hyperemia and administration of GTN,
respectively. FMD was also reported as
“FMD/ﬂow,” deﬁned as the maximal per-
cent change in vessel diameter divided by
percent change in ﬂow (peak instanta-
neous ﬂow  baseline instantaneous
ﬂow/baseline instantaneous ﬂow  100,
where baseline instantaneous ﬂow was
averaged over 1 min before pressure cuff
inﬂationandpeakinstantaneousﬂowwas
calculated immediately after cuff deﬂa-
tion), to create a stimulus-adjusted re-
sponse measure (10). A single observer
(D.Z.I.C.) obtained all measurements.
The intraobserver variability for re-
peated measurements of arterial diame-
ters at ﬂow-mediated vasodilatation was
0.01  0.0.005 mm (absolute diameter)
or 0.26  0.01% (percentage of the abso-
lute value of the brachial artery at ﬂow-
mediatedvasodilatation),whichissimilar
to that reported previously (7,11).
Assessment of renal hemodynamic
function
After the assessment of arterial stiffness
and endothelial function, a third intrave-
nous line was inserted into the right arm
and was connected to a syringe infusion
pump for administration of inulin and
paraaminohippurate (PAH). After collec-
tion of blood for inulin and PAH blank, a
priming infusion containing 25% inulin
(60 mg/kg) and 20% PAH (8 mg/kg) was
administered. Thereafter, inulin and PAH
were infused continuously at a rate calcu-
lated to maintain their respective plasma
concentrationsconstantat20and1.5mg/
dl. After a 90-min equilibration period,
blood was collected for inulin, PAH, and
hematocrit. Blood was further collected
every 30 min for 60 min for inulin and
PAH,andglomerularﬁltrationrate(GFR)
and effective renal plasma ﬂow (ERPF)
wereestimatedbysteady-stateinfusionof
inulin and PAH, respectively (8).
Sample collection and analytical
methods
Blood samples collected for inulin and
PAH determinations were immediately
centrifuged at 3,000 rpm for 10 min at
4°C. Plasma was separated, placed on ice,
and then stored at 70°C before the as-
say. Inulin and PAH were measured in
serum by colorimetric assays using an-
throne and N-(1-naphthyl)ethylenedia-
mine, respectively. The mean of two
baseline clearance periods represent GFR
and ERPF, expressed per 1.73 m
2. Renal
blood ﬂow (RBF) was derived using
ERPF/[1hematocrit]andrenalvascular
resistance derived by dividing the mean
arterial pressure by the RBF. All renal he-
Table 1—Baseline clinical characteristics
n 10
Sex (male/female) 5/5
Age (years) 43.1  3.9
A1C (%) 7.93  0.40




(g/min) 0.233  0.053
24-h Na
	 intake (mmol/
day) 199  25
Estimated protein intake
(g   kg
1   day
1) 1.03  0.15
Weight (kg) 79  5
Data are means  SEM.
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for body surface area.
Active plasma renin was measured
by a two-site immunoradiometric assay
in which two monoclonal antibodies to
human active renin are used. One anti-
bodywascoupledtobiotin,andthesec-
ond was radiolabeled for detection. The
sample containing active renin was in-
cubated simultaneously with both
antibodies to form a complex. The ra-
dioactivity of this complex was directly
proportional to the amount of immuno-
reactive renin present in the sample.
Plasma renin activity was measured
with a radioimmunoassay kit (Gamma-
Coat Plasma Renin Activity
125I RIA Kit,
CA-1533; DiaSorin, Stillwater, MN).
Plasma renin activity determination in-
volves an initial incubation of plasma to
generate angiotensin I, followed by
quantitation of angiotensin I by radio-
immunoassay. In the GammaCoat
Plasma Renin Activity
125I RIA Kit, the
antibody is immobilized onto the lower
inner wall of the GammaCoat tube. Af-
ter incubation of standards, unknown
samples, and
125I-labeled angiotensin I
in the GammaCoat tube, the reaction
mixture is removed by aspiration, and
the bound tracer is counted in a gamma
counter. A standard curve is constructed,
and the concentration of angiotensin I in
the unknown sample is obtained by
interpolation.
The urinary albumin excretion rate
was determined from three timed over-
night urine collections. The urinary al-
bumin concentration was determined
byimmunoturbidimetry.A1Cwasmea-
sured by high-performance liquid
chromatography.
Statistical analysis
Changes in renal and systemic hemody-
namic function in response to the DRI
were assessed using a repeated-measures
ANOVA. All statistical analyses were per-
formed using the statistical package SPSS
(SPSS for graduate students, version
14.0). The vascular data were obtained
and analyzed by a single observer
(D.Z.I.C.), who was blinded to the glyce-
mic day and renal hemodynamic
measurements.
RESULTS
Baseline clinical characteristics and
hemodynamic function
At baseline, subjects were normoalbu-
minuric and 24-h urine collections
demonstrated adherence to the pre-
scribed sodium and protein dietary
preparation. The mean serum estradiol
level was 138  36.5 pmol/l, consistent
withthelatefollicularphaseofthemen-
strual cycle. Baseline peripheral and
central blood pressure proﬁles, renal
function,arterialstiffness,andendothe-
lial function are described in Table 2.
Subjects were normotensive and had
normal renal function. No subjects ex-
hibited renal hyperﬁltration (deﬁned as
GFR 135 ml/min per 1.73 m
2)a t
baseline.
Renal and systemic hemodynamic
responses to a DRI
As expected, circulating plasma renin ac-
tivity decreased (from 0.40 to 0.13 ng  
ml
1   h
1, P 
 0.049) and plasma renin
increased (from 5.2 to 75.0 ng/l, P 

0.016) after 30 days of DRI administra-
tion. Peripheral blood pressure decreased
by 13/8 mmHg during clamped euglyce-
mia and 12/4 mmHg during clamped hy-
perglycemia compared with baseline
measurements (P  0.05), whereas heart
ratedidnotchange(Table2).DRIadmin-
istration also resulted in signiﬁcant de-
clines in central blood pressure during
clamped euglycemia and clamped hyper-
glycemia (P  0.05). During clamped eu-
glycemia and hyperglycemia, ERPF and
GFR increased proportionately (P 
0.05), so that net ﬁltration fraction did
not change.
Administration of a DRI resulted in
both a signiﬁcant reduction in the carotid
augmentation index during clamped eu-
glycemia and a decline in pulse wave ve-
locity during clamped hyperglycemia (all
P  0.05). The DRI also produced alter-
ations in endothelial function. Although
Table 2—Blood pressure, arterial stiffness, and endothelial function responses to a DRI in type 1 diabetes
Parameter
Before DRI After DRI
Euglycemia Hyperglycemia Euglycemia Hyperglycemia
Heart rate (bpm) 63  26 1  36 4  36 2  2
Blood pressure
Peripheral SBP (mmHg) 120  4 123  4 107  3* 111  4†
Peripheral DBP (mmHg) 70  27 2  26 2  3* 68  3†
Renal hemodynamic function
ERPF 558  27 606  29 665  24* 704  35†
GFR 105  3 117  5 114  3* 124  2†
Filtration fraction 0.19  0.01 0.20  0.001 0.18  0.01 0.18  0.01
RBF 914  58 984  65 1,049  59* 1,102  76†
Renal vascular resistance 0.082  0.013 0.086  0.010 0.080  0.013 0.078  0.007
Applanation tonometry
Central SBP (mmHg) 104  3 109  49 7  3* 103  3†
Augmentation index (%) 21.7  16.6 22.0  5.0 16.6  4.8* 18.7  4.6
Aortic PWV (m/s) 7.4  0.4 7.8  0.6 6.7  0.4 6.8  0.5†
Endothelial function
Flow (% change) 74.58  5.63 81.01  7.32 75.54  9.69 69.59  8.19
FMD (% change) 1.92  1.13 1.86  0.98 5.55  0.81* 5.63  0.62†
FMD/ﬂow 0.030  0.017 0.036  0.015 0.084  0.015* 0.094  0.016†
GTN (% change) 9.52  2.01 11.22  1.36 14.22  1.49* 15.85  1.46†
Data are means  SEM. *P  0.05 vs. pre-DRI parameter during clamped euglycemia. †P  0.05 vs. pre-DRI parameter during clamped hyperglycemia. DBP,
diastolic blood pressure; ﬂow, % change in instantaneous ﬂow; SBP, systolic blood pressure; PWV, pulse wave velocity.
Cherney and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 363the ﬂow stimulus did not change signiﬁ-
cantly with the DRI, FMD increased dur-
ing both clamped euglycemia (from
1.92  1.13 to 5.55  0.81%) and hy-
perglycemia (from 1.860.98 to 5.63
0.62) (Table 2). Compared with base-
line, FMD corrected for the ﬂow stimu-
lus (FMD/ﬂow) and the response to
GTN were also increased during
clampedeuglycemiaandhyperglycemia
(Table 2, Fig. 1).
CONCLUSIONS — Blockade of the
RAS is a critical approach to the manage-
mentofpatientswithtype1diabetes(12).
The objective of this pilot study was
therefore to examine the renal and pe-
ripheral vascular hemodynamic effects of
DRI monotherapy using aliskiren in sub-
jects with uncomplicated type 1 diabetes.
Our major ﬁndings were that aliskiren 1)
decreases peripheral and central blood
pressures, independent of glycemic sta-
tus, 2) has a signiﬁcant renal vasodilatory
effect, regardless of ambient glycemia,
and 3) increases arterial compliance and
endothelialfunctionasmeasuredbyFMD
and GTN responsiveness.
DRIs may block the RAS through a
variety of mechanisms. First, in addition
to conversion from angiotensin I by ACE,
angiotensin II can be generated from an-
giotensin I via non-ACE, chymostatin-
sensitivepathways,whicharenotaffected
by ACEIs, but are blocked by DRIs (13).
Second, circulating levels of angiotensin
peptides, including angiotensin II, in-
crease after ARB treatment, leading to an-
giotensin type 2 receptor activation and
possibly to vascular proliferative effects
(14). This effect is not seen with DRIs
(14). Third, ACEI and ARB therapies in-
crease circulating levels of renin and pro-
renin. These circulating factors bind to
the (pro)renin receptor [(P)RR], increas-
ingitscatalyticactivityandthegeneration
of both angiotensin I and angiotensin II
(12). In contrast, DRIs may inhibit (P)RR
activation (12). Fourth, direct binding of
renin and/or prorenin to the (P)RR may
stimulate signaling pathways associated
with cell injury, ultimately leading to an
increase in the expression of proﬁbrotic
mediators by mesangial cells (12). This
signaling cascade may be blocked using a
DRI (12). These mechanisms of action
may be important when the additive ef-
fect of a DRI to an ACEI or ARB is ex-
amined, because DRIs may mitigate
compensatory pathways that limit the
long-term efﬁcacy of ACEI- or ARB-
based monotherapies (4).
Our ﬁrst major observation was the
signiﬁcantperipheralantihypertensiveef-
fect of DRI monotherapy in humans with
type 1 diabetes during clamped euglyce-
mia and hyperglycemia. ACEIs and ARBs
have well-described antihypertensive ef-
fects in healthy humans and in those with
type 1 diabetes (15,16). In human sub-
jects with essential hypertension, DRI
monotherapy is associated with a 12.7/
9.7 mmHg reduction in blood pressure
(17); the 13/8 mmHg reduction in sys-
temic blood pressure that we observed in
normotensive subjects with uncompli-
cated type 1 diabetes was similar to this
previous report in nondiabetic subjects.
Moreover, we observed a signiﬁcant cen-
tral blood pressure reduction after DRI
therapy during clamped euglycemia and
hyperglycemia. These changes in central
blood pressures were similar in magni-
tude to the previously reported effects of
ACEIs(18).WhethertheeffectofACEIor
ARB therapy combined with a DRI would
have an additive antihypertensive effect
on central blood pressure clearly requires
future direct comparison studies. The an-
tihypertensive effect that we observed
during clamped hyperglycemia is of crit-
ical importance, as hyperglycemia can be
a vasoconstrictive and hypertensive stim-
ulus (19). Because patients with diabetes
are frequently exposed to hyperglycemia,
the ability of a DRI to control blood pres-
sure during ambient hyperglycemic con-
ditions is an important feature of this
drug.
Our second major observation was
that in subjects ingesting a carefully con-
trolled high-sodium diet, ERPF increased
by 16 and 14% during clamped euglyce-
miaandhyperglycemia,respectively.Pre-
vious studies examining the effect of
ACEIs and ARBs on renal hemodynamic
function have demonstrated a wide spec-
trum of renal vasodilatory responses; the
variability in the renal vascular response
to these drugs has been attributed to the
inﬂuences of sex, renal ﬁltration status,
sodium intake, ambient glycemia, and
the presence or absence of diabetes
(15,16,20). Fisher et al. (20) described
the renal hemodynamic effects of DRIs in
healthy, salt-depleted individuals. In that
study, administration of 300 mg of
aliskiren was associated with a 29% in-
crease in ERPF, which was greater than
the effect observed in their historical con-
trolsubjectswhoweretreatedwith25mg
of captopril. We have previously ob-
served that dietary sodium restriction can
paradoxically increase renal hemodynamic
effects in uncomplicated type 1 diabetes,
possibly through nonhemodynamic mech-
anisms (21). Whether the renal hemody-
namic effect of DRIs can be enhanced in
diabetic subjects through the use of di-
etarysodiumdepletionisnotknown.Our
results focus on DRI monotherapy, so fu-
ture studies will be necessary to examine
the additive effects of a DRI to an ACEI or
ARB in this patient population.
Our third major observation was the
signiﬁcant effect of the DRI on arterial
stiffness and endothelial function. In the
present set of experiments using a typical
therapeutic dose of the DRI, we observed
reductions in the carotid augmentation
index (23.5%) and pulse wave velocity
(12.8%) that were similar to the effects of
ACEIs that have been reported by others
(22).Inadditiontoeffectsonarterialstiff-
ness, we observed signiﬁcant positive ef-
fectsonendothelialfunction.Theeffectof
ACEI therapy on endothelial function is
variable; in obese, nondiabetic human
subjects, and in some studies involving
subjects with type 1 diabetes, ACEIs had
no effect on endothelial function (23,24).
In hypertensive individuals, ACEIs im-
prove ﬂow-mediated dilatation by 30–
40% (24). In the present study, we
observed a 65% increase in endothelial
function whether or not FMD was cor-
rected for the ﬂow stimulus. The DRI also
improved GTN responsiveness, indepen-
dent of glycemic status, suggesting that
this class of agents increases nitric oxide
bioavailability, similar to the effect of
ACEIs. As reviewed elsewhere, the phys-
iological impact related to the compensa-
tory rise in plasma renin after a DRI is not
known (4). Although the small sample
size precludes any deﬁnitive conclusions,
this pilot study suggests that the positive
blood pressure and renal hemodynamic
effects of DRI therapy extend to arterial
Figure 1—Effect of a DRI on endothelial func-
tion in type 1 diabetes (means  SEM). *P 

0.04 vs. baseline during clamped euglycemia.
†P 
 0.0001 vs. baseline during clamped
hyperglycemia.
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jects with uncomplicated type 1 diabetes.
This pilot study has important lim-
itations. First, the sample size was small
and may have limited our ability to de-
tect some differences in renal hemody-
namic parameters (such as renal
vascular resistance) and arterial stiff-
ness (such as the carotid augmentation
index during clamped hyperglycemia).
We attempted to minimize the effect of
the small sample size by using homoge-
neous study groups and by careful pre-
study dietary preparation. We also
decreased variability by using a study
design that allowed each subject to act
as his or her own control.
In summary, DRIs have signiﬁcant
beneﬁcial hemodynamic effects in the re-
nal and systemic circulations, leading to
reductions in peripheral and central
bloodpressures,renalvasodilatation,and
augmentedarterialcomplianceandendo-
thelial function in subjects with uncom-
plicated type 1 diabetes. The magnitude
of these effects is similar to that seen in
previous studies using ACEIs and ARBs.
This work highlights the need for future
physiological and clinical studies in hu-
mans that examine the effect of dual RAS
blockade using a DRI and ACEI or ARB
therapy.
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